Vitenskapelig artikkel

• Torgauten, Hilde Marie; Onyango, Therese Bredholt; Ljostveit, Sonja et al. (2024). Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients. (ekstern lenke)
• Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
• König, Marton; Torgauten, Hilde Marie; Tran, Trung et al. (2022). Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients with Multiple Sclerosis and Weak Immune Response after COVID-19 Vaccination. (ekstern lenke)
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie et al. (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. (ekstern lenke)
• Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)

Brev til redaktøren

• Nygaard, Gro Owren; Torgauten, Hilde Marie; Skattebøl, Lars et al. (2022). Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis. (ekstern lenke)

Poster

• König, Marton; Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)
• Rasmussen, Tilde; König, Marton; Lorentzen, Åslaug Rudjord et al. (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. (ekstern lenke)
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie et al. (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. (ekstern lenke)

Se en full oversikt over publikasjoner i Cristin